Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies

dc.contributor.authorBarbosa Alfaro, Deyanira
dc.contributor.authorAndrés Guerrero, Vanesa
dc.contributor.authorFernández Bueno, Iván
dc.contributor.authorGarcía Gutiérrez, María Teresa
dc.contributor.authorGil Alegre, María Esther
dc.contributor.authorMolina Martínez, Irene Teresa
dc.contributor.authorPastor Jimeno, José Carlos
dc.contributor.authorHerrero Vanrell, María Del Rocío
dc.contributor.authorBravo Osuna, Irene
dc.date.accessioned2023-06-17T08:25:34Z
dc.date.available2023-06-17T08:25:34Z
dc.date.issued2021-02-06
dc.description.abstractMany diseases affecting the posterior segment of the eye require repeated intravitreal injections with corticosteroids in chronic treatments. The periocular administration is a less invasive route attracting considerable attention for long-term therapies. In the present work, dexamethasone-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres (Dx-MS) were prepared using the oil-in-water (O/W) emulsion solvent evaporation technique. MS were characterized in terms of mean particle size and particle size distribution, external morphology, polymer integrity, drug content, and in vitro release profiles. MS were sterilized by gamma irradiation (25 kGy), and dexamethasone release profiles from sterilized and non-sterilized microspheres were compared by means of the similarity factor (f2). The mechanism of drug release before and after irradiation exposure of Dx-MS was identified using appropriate mathematical models. Dexamethasone release was sustained in vitro for 9 weeks. The evaluation of the in vivo tolerance was carried out in rabbit eyes, which received a sub-Tenon injection of 5 mg of sterilized Dx-MS (20–53 µm size containing 165.6 ± 3.6 µg Dx/mg MS) equivalent to 828 µg of Dx. No detectable increase in intraocular pressure was reported, and clinical and histological analysis of the ocular tissues showed no adverse events up to 6 weeks after the administration. According to the data presented in this work, the sub-Tenon administration of Dx-MS could be a promising alternative to successive intravitreal injections for the treatment of chronic diseases of the back of the eye.en
dc.description.departmentDepto. de Farmacia Galénica y Tecnología Alimentaria
dc.description.facultyFac. de Farmacia
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades (España)
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipUniversidad Complutense de Madrid
dc.description.sponsorshipConsejo Nacional de Ciencia y Tecnologίa (México)
dc.description.sponsorshipJunta de Castilla y León
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/71803
dc.identifier.doi10.3390/pharmaceutics13020228
dc.identifier.issn1999-4923
dc.identifier.officialurlhttps//doi.org/10.3390/pharmaceutics13020228
dc.identifier.relatedurlhttp://www.mdpi.com/journal/pharmaceutics
dc.identifier.urihttps://hdl.handle.net/20.500.14352/7071
dc.issue.number2
dc.journal.titlePharmaceutics
dc.language.isoeng
dc.page.initial228
dc.publisherMDPI
dc.relation.projectID(MAT 2017-83858-C2-1-R)
dc.relation.projectIDRETICS (RD16/0008/0001, RD16/0008/0004, RD16/0008/0009)
dc.relation.projectIDUCM (920415)
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.cdu615.4
dc.subject.keywordDexamethasone
dc.subject.keywordPoly(lactic-co-glycolic) acid
dc.subject.keywordOphthalmology
dc.subject.keywordMicrospheres
dc.subject.keywordPeriocular administration
dc.subject.keywordGamma sterilization
dc.subject.keywordTolerance
dc.subject.ucmTecnología farmaceútica
dc.titleDexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studiesen
dc.typejournal article
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublication14096cb3-8372-40d2-8fe1-79d0c4c1ddd7
relation.isAuthorOfPublication7692c146-b0ca-4ca6-a31b-0c591a4a3624
relation.isAuthorOfPublication43cca2c8-2da7-45dd-bce6-4b70a86a3877
relation.isAuthorOfPublicatione19672b5-d6f7-400a-b591-b903bc396955
relation.isAuthorOfPublication491381a5-fc5a-4cd5-a0b0-9b6cfdae6706
relation.isAuthorOfPublication.latestForDiscovery7692c146-b0ca-4ca6-a31b-0c591a4a3624

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pharmaceutics-13-00228.pdf
Size:
3.38 MB
Format:
Adobe Portable Document Format

Collections